{"issuance_frequency":"","notes_translated":{"fr":"L'hépatotoxicité causée par l'exposition à un médicament ou à un autre agent non infectieux est une blessure ou des dommages au foie qui peuvent être associés à une déficience de la fonction hépatique. Le présent document vise à exposer les éléments à prendre en compte pour satisfaire aux exigences de détection, d'évaluation, d'atténuation et de déclaration de l'hépatotoxicité causée par les produits de santé à usage humain. Utilisés seuls et avec d'autres produits de santé, des aliments ou d'autres xénobiotiques avant l'autorisation de mise en marché par Santé Canada.","en":"Hepatotoxicity caused by exposure to a drug or non-infectious agent is injury or damage to the liver that may be associated with impaired liver function. This document is intended to provide basic considerations for the detection, assessment, mitigation and reporting requirements of hepatotoxicity caused by human health products, both alone and in the presence of other health products, foods or xenobiotics, prior to market authorization by Health Canada."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"d8a9915b-18e6-4549-8c42-22aa401c9fdb","metadata_created":"2021-07-07T16:42:03.827289","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T16:42:03.827295","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Document d'orientation","évaluation préalable à la mise sur le marché","hépatotoxicité","exposition à un médicament ou à un agent non infectieux","dommages au foie","altération de la fonction hépatique","détection","évaluation","atténuation","exigences de déclaration de l'hépatotoxicité","produits de santé humaine","produits de santé"],"en":["Guidance document","pre-market evaluation","hepatotoxicity","exposure to a drug or non-infectious agent","damage to the liver","impaired liver function","detection","assessment","mitigation","reporting requirements of hepatotoxicity","human health products","health products"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice : Évaluation pré-commercialisation de l'hépatotoxicité des produits de santé","en":"Guidance Document: Pre-market Evaluation of Hepatotoxicity in Health Products"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"d8a9915b-18e6-4549-8c42-22aa401c9fdb","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"24746c28-2afe-4be5-988f-74d4f6da4655","related_relationship":"","name_translated":{"fr":"Ligne directrice : Évaluation pré-commercialisation de l'hépatotoxicité des produits de santé","en":"Guidance Document: Pre-market Evaluation of Hepatotoxicity in Health Products"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Pre-market Evaluation of Hepatotoxicity in Health Products","language":["en"],"created":"2021-07-07T16:42:03.899400","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/hepatotoxicity-pre-market-evaluation.html","last_modified":null,"position":0,"revision_id":"ad85aa41-366e-4731-95dd-512bdbd66ba0","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"d8a9915b-18e6-4549-8c42-22aa401c9fdb","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"30d5cf58-127b-407e-8cf0-43a3e8c6943e","related_relationship":"","name_translated":{"fr":"Ligne directrice : Évaluation pré-commercialisation de l'hépatotoxicité des produits de santé","en":"Guidance Document: Pre-market Evaluation of Hepatotoxicity in Health Products"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Pre-market Evaluation of Hepatotoxicity in Health Products","language":["fr"],"created":"2021-07-07T16:42:03.899405","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/hepatoxicite-pre-commercialisation.html#a1","last_modified":null,"position":1,"revision_id":"ad85aa41-366e-4731-95dd-512bdbd66ba0","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2016-06-27 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"d8a9915b-18e6-4549-8c42-22aa401c9fdb","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"Hepatotoxicity caused by exposure to a drug or non-infectious agent is injury or damage to the liver that may be associated with impaired liver function. This document is intended to provide basic considerations for the detection, assessment, mitigation and reporting requirements of hepatotoxicity caused by human health products, both alone and in the presence of other health products, foods or xenobiotics, prior to market authorization by Health Canada.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document: Pre-market Evaluation of Hepatotoxicity in Health Products","revision_id":"ad85aa41-366e-4731-95dd-512bdbd66ba0"}